Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), drawn from the whole corpus: 34 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Five-year survival under 40% for PTCL-NOS with no new first-line regimen for non-CD30 disease.
Randomised evidence for transplant consolidation is lacking.
T-cell CAR-T faces fratricide and T-cell aplasia.
Most subtypes too rare for conventional phase 3 trials.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
Relapsed or refractory peripheral T-cell lymphoma
Confirmatory Ro-CHOP trial negative.
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.
Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.